Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 23 September 2025

This trial will evaluate long-term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusionLong-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Trial purpose

Medical clipboardLong-term follow-up

Tumor type

Multi-Cancer Multi-Cancer

Clinical summary

Summary

People who received AdaptImmune (ADP) adoptive cell therapy will be enrolled in this non-therapeutic, multi-centre, long-term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

No treatments will be administered in this study.

Conditions

This trial is treating people with neoplasms who have completed ADP sponsored or supported clinical trials with adoptive cell therapy

Eligibility

Inclusion

  • Participants who have received at least one dose of ADP adoptive cell therapy agent.
  • Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
  • Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The investigator is responsible for review of medical history.
  • Capable of giving signed informed consent.

Exclusion

- None

Inclusion

  • You have previously participated in a certain specific clinical trial.
  • You have had a certain type of treatment or surgical procedure.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Adaptimmune

Scientific Title

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information